Co-founded by faculty members at the University of Miamiâs The Miami Project to Cure Paralysis, Truvitech LLC, is a biotechnology startup structured around accelerating the discovery of therapeutics and improving the quality of life for patients during treatment. Seeking to change how drug targets are discovered and are drugs developed and combined for maximal therapeutic impact, Truvitech enables the cross-discipline collaboration and creativity of clinicians, biologists, chemists, and computer scientists. Application of Truvitech approach has resulted in a promising compound that is currently in preclinical development for treating central nervous system (CNS) injuries. Further, proof-of-concept applications for other disease models have demonstrated the high portability of the platform. The firm's approach is being used to develop drugs for lymphoma, with another the planning phase for a Diabetic Kidney Disease drug. The firm's Truvitechâs patent-pending technology uses a unique combination of biochemical profiling, cell-based screening, and machine learning to rapidly discover responsive pharmacological targets. The two key components of the platform are a specially designed chemical probe library and a unique algorithm for data analysis. The employed technique has often identified several druggable targets: critical information for developing efficacious drugs, and also valuable for designing optimal drug combinations. A bonusis that the platform identifies biological components whose engagement must be avoided to maximize therapeutic efficacy (anti-targets
